与苯氟雷司暴露相关的心脏手术累积发生率:基于赔偿索赔数据的回顾性分析
该研究基于法国苯氟雷司赔偿索赔数据构建了报告不足的建模框架,结合社会学调查与销售数据估计心脏瓣膜手术的累积发生率。发现约6个月暴露为毒性阈值,至少1690人(95%CI 1290至2320)需瓣膜手术,累积发生率为每万使用者3.68(95%CI 2.68至5.34)或每万风险人年3.22(95%CI 2.48至4.39)。
要点
- 苯氟雷司暴露约6个月为毒性阈值。
- 法国至少1690人(95%CI 1290至2320)因暴露需心脏瓣膜手术。
- 累积发生率为每万使用者3.68(95%CI 2.68至5.34)。
核心结论
- 回顾性赔偿索赔数据可用于估计药物相关损伤的累积发生率并提供流行病学信息。
- 研究结果尚属初步,但与既往采用不同方法获得的结果一致。
研究设计与样本
- 基于法国苯氟雷司赔偿索赔数据的回顾性分析,结合苯氟雷司使用者的社会学调查数据、销售数据及治疗时长数据。
- 建立药物损害回顾性索赔报告不足的建模框架,包含与病例随时间流失相关的纵向成分和与不完整报告相关的横截面成分。
主要发现
- 发现约6个月暴露的毒性阈值。
- 法国至少1690人(95%CI 1290至2320)需心脏手术置换或修复因苯氟雷司暴露受损的瓣膜。
- 累积发生率为每万苯氟雷司使用者3.68(95%CI 2.68至5.34)或暴露阈值以上每万风险人年3.22(95%CI 2.48至4.39)。
局限性
- 回顾性赔偿索赔数据易受选择偏倚和报告偏倚影响。
- 研究结果尚属初步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data on retrospective compensation claims for injuries caused by pharmaceutical drugs are prone to selection and reporting biases. Nevertheless, this case study of the antidiabetic drug benfluorex shows that such data can be used to estimate the cumulative incidence of drug-related injury, and to provide insights into its epidemiology. To this end, we develop a modelling framework for under-reporting of retrospective claims for compensation arising from drug damage. The model involves a longitudinal component related to attrition of cases over time, and a cross-sectional component related to incomplete reporting. We apply this model to cardiac valve surgery necessitated by exposure to benfluorex. Benfluorex was marketed in France between 1976 and 2009, when it was withdrawn because it caused valvular heart disease. A scandal erupted in 2010 over the scale of the damage caused by the drug. Since then, no further estimates of cumulative incidence have been published, though thousands of claims for compensation have been processed. The analysis combines compensation claims data and sociological survey data on benfluorex users, together with data on benfluorex sales and duration of treatment. We find a threshold of toxicity at about 6 months' exposure, and that at least 1690 individuals (95% CI 1290 to 2320) needed heart surgery to replace or repair valves damaged by exposure to benfluorex in France: a cumulative incidence of 3.68 per 10,000 (95% CI 2.68 to 5.34) benfluorex users or 3.22 per 10,000 (95% CI 2.48 to 4.39) person-years at risk above the exposure threshold. While these findings are tentative, they are consistent with those obtained previously using very different methods.
引用
- Farrington P, Lellinger S. Cumulative incidence of cardiac surgery associated with exposure to benfluorex: A retrospective analysis based on compensation claims data. Stat Med. 2024. PMID: 38693582. doi:10.1002/sim.10100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。